血运重建与非血运重建治疗对慢性肢体威胁性缺血预后比较:日本区域保险索赔分析
基于日本静冈国保数据库的回顾性分析,纳入2012年4月至2020年9月3160例伴组织缺损的慢性肢体威胁性缺血患者,其中559例接受非血运重建治疗(99.1%为前列地尔注射),589例接受血运重建。倾向性评分匹配后,血运重建组372例的1年无截肢生存率显著高于非血运重建组(58.0% vs 45.7%,p=.014)。亚组分析显示男性、糖尿病及严重创面患者获益更明显,而女性及非严重创面患者未见差异。
要点
- 倾向性评分匹配后,血运重建组1年无截肢生存率58.0% vs 非血运重建组45.7%(p=.014)。
- 男性(HR 0.59,95%CI 0.47-0.75)、糖尿病(HR 0.67,95%CI 0.50-0.89)及严重创面(HR 0.76,95%CI 0.61-0.93)患者血运重建获益更明显。
- 女性(HR 1.06,95%CI 0.78-1.45)及非严重创面(HR 0.87,95%CI 0.58-1.30)患者两组间无显著差异。
核心结论
- 该日本区域队列研究显示,伴组织缺损的慢性肢体威胁性缺血患者接受血运重建后无截肢生存率可能较非血运重建治疗提高,但女性和非严重创面患者除外。
- 原文结论指出需要额外研究来进一步阐明这些结果。
研究设计与样本
- 回顾性分析,利用日本静冈国保数据库(区域代表性纵向队列),纳入2012年4月至2020年9月伴组织缺损(溃疡和坏疽)的慢性肢体威胁性缺血患者。
- 共识别3160例伴组织缺损的慢性肢体威胁性缺血患者,其中559例接受非血运重建治疗,589例接受血运重建。
- 主要终点为无截肢生存率,采用倾向性评分匹配(1:1)后评估。
主要发现
- 非血运重建治疗以前列地尔注射为主(99.1%)。
- 倾向性评分匹配后,血运重建组372例的1年无截肢生存率为58.0%,非血运重建组为45.7%(p=.014)。
- 亚组分析中,男性患者血运重建的HR为0.59(95%CI 0.47-0.75),糖尿病患者HR为0.67(95%CI 0.50-0.89),严重创面患者HR为0.76(95%CI 0.61-0.93)。
- 女性患者HR为1.06(95%CI 0.78-1.45),非严重创面患者HR为0.87(95%CI 0.58-1.30),两组间无显著差异。
关键数值与推荐
- 倾向性评分匹配后血运重建组(372例)1年无截肢生存率58.0% vs 非血运重建组45.7%(p=.014)。
- 男性亚组HR 0.59(95%CI 0.47-0.75),糖尿病亚组HR 0.67(95%CI 0.50-0.89),严重创面亚组HR 0.76(95%CI 0.61-0.93)。
- 女性亚组HR 1.06(95%CI 0.78-1.45),非严重创面亚组HR 0.87(95%CI 0.58-1.30)。
- 非血运重建治疗中前列地尔注射占99.1%。
临床怎么用
- 原文结论未据此给出具体临床推荐。
局限性
- 原文结论指出需要额外研究来进一步阐明这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: While the prevailing practice for treating chronic limb threatening ischaemia (CLTI) is revascularisation, there is a limited understanding of disease progression in patients with CLTI who do not undergo this intervention. This study compared the prognosis of CLTI patients with tissue loss who underwent revascularisation with the prognosis of those who were managed with non-revascularisation treatment, investigating the efficacy of revascularisation in improving the outcome of patients with CLTI. METHODS: Utilising the Shizuoka Kokuho Database, a regionally representative longitudinal cohort in Japan, this retrospective analysis examined CLTI patients with tissue loss (ulcer and gangrene), between April 2012 and September 2020, identifying two distinct cohorts: those receiving non-revascularisation treatment and those undergoing revascularisation. The primary endpoint was amputation free survival, evaluated in both cohorts after applying propensity score matching. RESULTS: Of the 3 160 CLTI patients with tissue loss, 559 received non-revascularisation treatment and 589 underwent revascularisation. The non-revascularisation treatment predominantly involved prostaglandin E1 injections (99.1%). After one to one propensity score matching, the revascularisation cohort (372 patients) exhibited a markedly enhanced amputation free survival rate compared with their non-revascularisation counterparts (amputation free survival rate at one year: 58.0% vs. 45.7%, p = .014). Subgroup analyses underscored the greater efficacy of revascularisation across multiple categories, including males (hazard ratio [HR] 0.59, 95% confidence interval [CI] 0.47 - 0.75), patients with diabetes mellitus (HR 0.67, 95% CI 0.50 - 0.89), and patients with severe wounds (HR 0.76, 95% CI 0.61 - 0.93). However, the analysis did not find differences between the revascularisation and non-revascularisation treatment groups among female patients (HR 1.06, 95% CI 0.78 - 1.45) and patients with non-severe wounds (HR 0.87, 95% CI 0.58 - 1.30). CONCLUSION: This regional Japanese cohort study revealed a potential enhancement in the amputation free survival rate post-revascularisation for CLTI patients with tissue loss compared with non-revascularisation treatment, except in female patients and patients with non-severe wounds. Additional studies are needed to further elucidate these results.
引用
- Shintani T, Nakatani E, Kaneda H, et al. Editor's Choice - Comparison of Prognosis in Chronic Limb Threatening Ischaemia after Revascularisation versus Non-revascularisation Treatment: Analysis of Japanese Regional Insurance Claims. Eur J Vasc Endovasc Surg. 2025. PMID: 40404043. doi:10.1016/j.ejvs.2025.05.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。